Clinical Data Boehringer/Zealand dual-acting drug causes 16.6% weight loss PharmaphorumBoehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.Metabolic & GLP-1Read full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide. Metabolic & GLP-1 Read full story Post navigation Previous: BioMarin acquires Amicus Therapeutics for $4.8bnNext: Seaport and Hemab target $180m IPOs as biotech listings accumulate Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026